Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 82

1.

Chemistry and pharmacology of imexon and related cyanoaziridines.

Remers WA, Dorr RT.

Curr Med Chem. 2012;19(33):5745-53.

PMID:
22998528
[PubMed - indexed for MEDLINE]
2.

Chemical basis for the biological activity of imexon and related cyanoaziridines.

Iyengar BS, Dorr RT, Remers WA.

J Med Chem. 2004 Jan 1;47(1):218-23.

PMID:
14695835
[PubMed - indexed for MEDLINE]
3.

Anti-tumor activity and mechanism of action for a cyanoaziridine-derivative, AMP423.

Dorr RT, Wisner L, Samulitis BK, Landowski TH, Remers WA.

Cancer Chemother Pharmacol. 2012 Apr;69(4):1039-49. doi: 10.1007/s00280-011-1784-8. Epub 2011 Dec 21.

PMID:
22186884
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Novel antitumor 2-cyanoaziridine-1-carboxamides.

Iyengar BS, Dorr RT, Alberts DS, Hersh EM, Salmon SE, Remers WA.

J Med Chem. 1999 Feb 11;42(3):510-4.

PMID:
9986721
[PubMed - indexed for MEDLINE]
5.

Antiproliferative and antitumor activity of the 2-cyanoaziridine compound imexon on tumor cell lines and fresh tumor cells in vitro.

Hersh EM, Gschwind CR, Taylor CW, Dorr RT, Taetle R, Salmon SE.

J Natl Cancer Inst. 1992 Aug 19;84(16):1238-44.

PMID:
1640482
[PubMed - indexed for MEDLINE]
6.

Phase I trial of imexon in patients with advanced malignancy.

Dragovich T, Gordon M, Mendelson D, Wong L, Modiano M, Chow HH, Samulitis B, O'Day S, Grenier K, Hersh E, Dorr R.

J Clin Oncol. 2007 May 1;25(13):1779-84.

PMID:
17470869
[PubMed - indexed for MEDLINE]
7.

Preclinical antitumor activity, pharmacokinetics and pharmacodynamics of imexon in mice.

Pourpak A, Meyers RO, Samulitis BK, Sherry Chow HH, Kepler CY, Raymond MA, Hersh E, Dorr RT.

Anticancer Drugs. 2006 Nov;17(10):1179-84.

PMID:
17075317
[PubMed - indexed for MEDLINE]
8.

Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma.

Moehler TM, Feneberg R, Ho AD, Golenkov AK, Ludwig H, Kropff M, Khuageva NK, Hajda J, von Broen I, Goldschmidt H.

Anticancer Drugs. 2010 Aug;21(7):708-15. doi: 10.1097/CAD.0b013e32833b975b.

PMID:
20571355
[PubMed - indexed for MEDLINE]
9.

Induction of mitochondrial changes in myeloma cells by imexon.

Dvorakova K, Waltmire CN, Payne CM, Tome ME, Briehl MM, Dorr RT.

Blood. 2001 Jun 1;97(11):3544-51.

PMID:
11369649
[PubMed - indexed for MEDLINE]
Free Article
10.

Induction of apoptosis and cell cycle arrest by imexon in human pancreatic cancer cell lines.

Dorr RT, Raymond MA, Landowski TH, Roman NO, Fukushima S.

Int J Gastrointest Cancer. 2005;36(1):15-28.

PMID:
16227632
[PubMed - indexed for MEDLINE]
11.

Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon.

Dvorakova K, Payne CM, Tome ME, Briehl MM, McClure T, Dorr RT.

Biochem Pharmacol. 2000 Sep 15;60(6):749-58.

PMID:
10930529
[PubMed - indexed for MEDLINE]
12.

Imexon-based combination chemotherapy in A375 human melanoma and RPMI 8226 human myeloma cell lines.

Scott J, Dorr RT, Samulitis B, Landowski TH.

Cancer Chemother Pharmacol. 2007 May;59(6):749-57. Epub 2007 Feb 28.

PMID:
17333195
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Correlates of imexon sensitivity in human multiple myeloma cell lines.

Samulitis BK, Landowski TH, Dorr RT.

Leuk Lymphoma. 2006 Jan;47(1):97-109.

PMID:
16321833
[PubMed - indexed for MEDLINE]
14.

Preclinical pharmacokinetics and antitumor activity of imexon.

Dorr RT, Liddil JD, Klein MK, Hersh EM.

Invest New Drugs. 1995;13(2):113-6.

PMID:
8617572
[PubMed - indexed for MEDLINE]
15.

Imexon-induced apoptosis in multiple myeloma tumor cells is caspase-8 dependent.

Evens AM, Prachand S, Shi B, Paniaqua M, Gordon LI, Gartenhaus RB.

Clin Cancer Res. 2004 Feb 15;10(4):1481-91.

PMID:
14977852
[PubMed - indexed for MEDLINE]
Free Article
16.

Pharmaceutical development of a lyophilised dosage form for the investigational anticancer agent Imexon using dimethyl sulfoxide as solubilising and stabilising agent.

den Brok MW, Nuijen B, Lutz C, Opitz HG, Beijnen JH.

J Pharm Sci. 2005 May;94(5):1101-14.

PMID:
15793808
[PubMed - indexed for MEDLINE]
17.

Imexon augments sensitivity of human lymphoma cells to ionizing radiation: in vitro experimental study.

Cho H, Koto M, Riesterer O, Molkentine DP, Giri U, Milas L, Story MD, Ha CS, Raju U.

Anticancer Res. 2009 Nov;29(11):4409-15.

PMID:
20032386
[PubMed - indexed for MEDLINE]
Free Article
18.

Imexon activates an intrinsic apoptosis pathway in RPMI8226 myeloma cells.

Dvorakova K, Payne CM, Landowski TH, Tome ME, Halperin DS, Dorr RT.

Anticancer Drugs. 2002 Nov;13(10):1031-42.

PMID:
12439337
[PubMed - indexed for MEDLINE]
19.

Suppression of human lymphoma development in the severe combined immune-deficient mouse by imexon therapy.

Hersh EM, Grogan TM, Funk CY, Taylor CW.

J Immunother Emphasis Tumor Immunol. 1993 Feb;13(2):77-83.

PMID:
8391308
[PubMed - indexed for MEDLINE]
20.

Molecular and cellular characterization of imexon-resistant RPMI8226/I myeloma cells.

Dvorakova K, Payne CM, Tome ME, Briehl MM, Vasquez MA, Waltmire CN, Coon A, Dorr RT.

Mol Cancer Ther. 2002 Jan;1(3):185-95.

PMID:
12467213
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk